Plenary Session

Latest Episodes:

1.24 Useless Medical Conferences and Dr. Adam Obley on Vascepa, Fish Oil, Vitamin D and Methotrexate Nov 20, 2018

Show notes

In this episode we discuss John Ioannidis' article on the uselessness of medical conferences, published in JAMA: "Are Medical Conferences Useful? And for Whom?", followed by an interview with return-guest Dr. Adam Obley on a few recent clinical trials: Vascepa, fish oil, vitamin D, and methotrexate. Medical conferences: doi.org/10.1001/jama.2012.360

1.23 BONUS! Developing Technology with Fewer Reversals: Maybe We Need More Translation Failure Nov 15, 2018

Show notes

This BONUS episode is the recording of a lecture given as part of the Biomedical Engineering Seminar series at Oregon Health & Science University on November 9, 2018. The talk is on how to move technological devices to the clinic with fewer reversals.

1.22 Elo-Pom-Dex, Immunotherapy Combos, Inherent Bias, and the FDA with Dr. Erick Turner Nov 13, 2018

Show notes

In this episode, we tackle the recent papers in the New England Journal of Medicine on "Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma" and "Immunotherapy Combinations in Multiple Myeloma", as well as a comment in The Lancet Oncology's editorial "9 Weeks That Matter for Patients With Gastric Cancer". We conclude with an interview with Dr. Erick Turner of OHSU on the FDA, regulatory capture, selective reporting, and transparency. Elo-pom-dex: http://doi.org/10.1056/NEJMoa1805762 Immunotherapy combinations: http://doi.org/10.1056/NEJMp1803602 9 weeks that matter: http://doi.org/10.1016/S1470-2045(18)30752-6 Dr. Turner's seminal paper: https://doi.org/10.1056/NEJMsa065779

1.21 Nab-Paclitaxel in CCA, OS of PALOMA-3, Transparency, and Dr. Talal Hilal's Advice for Trainees Nov 06, 2018

Show notes

In this episode we question the conclusions of the phase II trial "Nab-Paclitaxel and Gemcitabine as First-line Treatment of Advanced or Metastatic Cholangiocarcinoma", review the long-term overall survival results from PALOMA-3, discuss Dr. Gyawali et al.'s paper on the need for transparency in reporting harms from cancer drugs, and interview Dr. Talal Hilal from the Scottsdale Mayo Clinic on his advice for trainees. Nab-paclitaxel and gemcitabine: doi.org/10.1001/jamaoncol.2018.3277 Palbociclib and fulvestrant: doi.org/10.1056/NEJMoa1810527 Reporting harms: doi.org/10.1136/bmj.k4383

1.20 Precision Oncology: Some Benefit, Mostly Hype and Mentorship with Dr. Andrae Vandross Oct 30, 2018

Show notes

We begin this episode analyzing the unrepentant hype of precision oncology in a monologue that was originally one half of a debate titled: "Is Precision Oncology Generating Patient Benefit or Just Hype?" We conclude with an interview with Dr. Andrae Vandross on the mentor/mentee relationship.

1.19 BONUS! Introduction to Cancer Drug Policy Oct 26, 2018

Show notes

This BONUS episode is the recording of a lecture given as part of a Cancer Intersession course for med students at Oregon Health & Science University on October 25, 2018. The talk is an introduction to cancer drug policy.

1.18 IMpassion130 and Hot-Spotting with Dr. Brian Chan Oct 23, 2018

Show notes

In this episode we evaluate the IMpassion130 trial on the use of atezolizumab in triple-negative breast cancer. We also interview Dr. Brian Chan of OHSU on a randomized controlled trial he's running that tests whether Dr. Gawande's idea of "hot-spotting" -- tailoring interventions to medically complex patients -- does decrease hospitalizations. IMpassion130: doi.org/10.1056/NEJMoa1809615 Hot-spotting: https://www.newyorker.com/magazine/2011/01/24/the-hot-spotters

1.17 BONUS! Interpretation of Cancer Clinical Trials Oct 22, 2018

Show notes

This BONUS episode is the recording of a two-part talk addressed to oncology fellows given at Oregon Health & Science University on October 5 and October 12, 2018. The talk is on how to interpret cancer clinical trials.

1.16 BONUS! Crowdsourcing Data Analysis and Medical Reversal: Why 40% of What We Do is Wrong Oct 17, 2018

Show notes

This BONUS episode is the recording of the Hospitalist Grand Rounds given at Oregon Health & Science University on October 11, 2018. The talk is on medical reversal. Before the talk we discuss the paper "Many Analysts, One Data Set: Making Transparent How Variations in Analytic Choices Affect Results" by Silberzahn et al., published in Advances in Methods and Practices in Psychological Science. Paper: doi.org/10.1177/2515245917747646

1.15 Minimally Effective Treatments, CheckMate 331, and Dr. Adam Obley on Low-Value Healthcare Oct 16, 2018

Show notes

In this episode we review the recent paper in Nature Reviews Clinical Oncology by Booth, C.M. and Detsky, A.S. titled "Why patients receive treatments that are minimally effective?". We discuss the failure of CheckMate 331 to meet its primary endpoint despite having received accelerated FDA approval. Finally, we bring back Dr. Adam Obley (from episode 1.01) to talk about low-value healthcare, medical education, social media, and more!

Our TOPPODCAST Picks

Follow Us

Stay Connected

Related Podcasts

Links

Stay Connected